PRESS RELEASES

Date Title and Summary View
Toggle Summary Regulus Therapeutics Announces Private Placement of Equity
Definitive Agreement for $34.6 Million in Gross Proceeds LA JOLLA, Calif. , Nov. 24, 2021 /PRNewswire/ -- Regulus Therapeutics Inc.  (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today
View HTML
Toggle Summary Regulus Therapeutics Reports Third Quarter 2021 Financial Results and Recent Updates
-Company advances RGLS8429 for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)- -Validating sections of IND-enabling toxicity studies for RGLS8429 completed- -IND submission and Phase 1 initiation expected in Q2 2022- -Data from first cohort of patients in Phase 1b clinical
View HTML
Toggle Summary Regulus Therapeutics Announces Timing for Third Quarter 2021 Financial Results Webcast and Conference Call
SAN DIEGO , Nov. 3, 2021 /PRNewswire/ --  Regulus Therapeutics Inc.  (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that it will report financial results and highlights
View HTML
Toggle Summary Regulus Therapeutics Announces Strategic Prioritization of RGLS8429, its Next-Generation Candidate for the Treatment of Autosomal Dominant Polycystic Kidney Disease
-Company will advance RGLS8429 supported by strong preclinical data and superior pharmacologic profile as compared to first-generation RGLS4326- -Validating sections of IND-enabling toxicity studies for RGLS8429 have been completed, with IND submission and Phase 1 initiation expected in Q2 2022-
View HTML
Toggle Summary Regulus Therapeutics' Director David Baltimore Receives 2021 Lasker-Koshland Special Achievement Award in Medical Science
SAN DIEGO , Sept. 30, 2021 /PRNewswire/ --  Regulus Therapeutics Inc .  (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that David Baltimore , Ph.D., a director of Regulus,
View HTML
Toggle Summary Regulus Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
SAN DIEGO , Sept. 9, 2021 /PRNewswire/ --  Regulus Therapeutics Inc.  (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that Jay Hagan , President and Chief Executive Officer
View HTML
Toggle Summary Regulus Therapeutics Reports Second Quarter 2021 Financial Results and Recent Updates
Completed Preparations and Request for FDA Meeting to Obtain Feedback on Approach to Addressing Remaining Hold Requirements Completed Enrollment in Second Cohort of Trial; Topline Data Expected in the Fourth Quarter Extended Expected Cash Runway into Q4 2022 with $15.4 Million Raised through its
View HTML
Toggle Summary Regulus Therapeutics Announces Timing for Second Quarter 2021 Financial Results Webcast and Conference Call
--Company also Announces Participation in a Panel Discussion at the 2021 Wedbush PacGrow Healthcare Conference SAN DIEGO , Aug, 3, 2021 /PRNewswire/ --  Regulus Therapeutics Inc.  (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting
View HTML
Toggle Summary Regulus Therapeutics Presents Additional Data from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program at PKD Connect 2021
Study demonstrates clinical proof of mechanism with statistically significant increases in polycystin levels following RGLS4326 treatment in the first cohort of patients with ADPKD Trends indicate further increases in polycystin levels may be achievable with longer term and, potentially, less
View HTML
Toggle Summary Regulus Therapeutics to Present Additional Data from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program at PKD Connect 2021
SAN DIEGO , June 21, 2021 /PRNewswire/ --  Regulus Therapeutics Inc .  (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that it will present new preclinical data and
View HTML